SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
NCT06210438 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2024-01-18
Summary
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
Conditions
- TNBC
- Brain Metastasis
Interventions
- DRUG
-
SHR-A1921 + Bevacizumab
SHR-A1921 + Bevacizumab
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun wang · Fudan University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-01
- Primary Completion
- 2025-06-30
- Completion
- 2026-06-30
Countries
- China
Study Locations
More Related Trials
-
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 ·Status: RECRUITING ·Phase: PHASE2
-
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
NCT06470672 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
NCT07177950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
NCT07041437 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases
NCT06975462 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
NCT04296370 ·Status: UNKNOWN ·Phase: PHASE3
-
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
NCT06786026 ·Status: RECRUITING ·Phase: PHASE2
-
Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
NCT05132790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer
NCT06411457 ·Status: RECRUITING ·Phase: PHASE2
-
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.
NCT04395989 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
NCT05862064 ·Status: RECRUITING ·Phase: PHASE3
-
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
NCT01658033 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
NCT05792410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
NCT06042894 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332 ·Status: RECRUITING ·Phase: PHASE3
-
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060 ·Status: RECRUITING ·Phase: PHASE3
-
Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy
NCT05303038 ·Status: UNKNOWN ·Phase: PHASE2
-
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
NCT03945604 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT03927456 ·Status: UNKNOWN ·Phase: PHASE3
-
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
NCT06592625 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
NCT05681728 ·Status: UNKNOWN ·Phase: PHASE2
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED